Published in Gastroenterology on June 01, 1998
Tips Underdilatation in Patients With Cirrhosis | NCT03363412
Now there are many (stages) where before there was one: In search of a pathophysiological classification of cirrhosis. Hepatology (2010) 2.68
Guidelines on the management of ascites in cirrhosis. Gut (2006) 1.81
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Hand-assisted laparoscopic splenectomy and devascularization of the upper stomach in the management of gastric varices. World J Surg (2006) 1.12
Effect of transjugular intrahepatic portosystemic shunt on pulmonary gas exchange in patients with portal hypertension and hepatopulmonary syndrome. World J Gastroenterol (2005) 1.05
Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci (2006) 1.04
The transjugular intrahepatic portosystemic shunt in the treatment of portal hypertension: current status. Int J Hepatol (2012) 1.00
Diagnosis and therapy of ascites in liver cirrhosis. World J Gastroenterol (2011) 0.99
Transjugular intrahepatic portosystemic shunt versus paracentesis plus albumin in patients with refractory ascites who have good hepatic and renal function: a prospective randomized trial. J Gastroenterol (2010) 0.96
Cirrhosis and its complications: evidence based treatment. World J Gastroenterol (2014) 0.93
Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension. J Gastroenterol (2012) 0.92
Clinical outcomes of transjugular intrahepatic portosystemic shunt for portal hypertension: Korean multicenter real-practice data. Clin Mol Hepatol (2014) 0.90
Evaluation and management of patients with refractory ascites. World J Gastroenterol (2009) 0.89
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Physiopathology of splanchnic vasodilation in portal hypertension. World J Hepatol (2010) 0.87
Clinical outcome and predictors of survival after TIPS insertion in patients with liver cirrhosis. World J Gastroenterol (2012) 0.86
Viral cirrhosis: an overview of haemostatic alterations and clinical consequences. Mediterr J Hematol Infect Dis (2009) 0.85
Transjugular intrahepatic portosystemic shunt. Clin Liver Dis (2014) 0.84
Cognitive Impairment Predicts The Occurrence Of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt. Am J Gastroenterol (2016) 0.84
Clinical effects and complications of TIPS for portal hypertension due to cirrhosis: a single center. World J Gastroenterol (2013) 0.83
Role of TIPS in Improving Survival of Patients with Decompensated Liver Disease. Int J Hepatol (2011) 0.83
Predictors of large volume paracantesis induced circulatory dysfunction in patients with massive hepatic ascites. J Cardiovasc Dis Res (2010) 0.82
Transjugular intrahepatic portosystemic shunt: indications, contraindications, and patient work-up. Semin Intervent Radiol (2014) 0.81
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol (2005) 0.80
Pathogenetic background for treatment of ascites and hepatorenal syndrome. Hepatol Int (2008) 0.79
Three-dimensional C-arm CT-guided transjugular intrahepatic portosystemic shunt placement: Feasibility, technical success and procedural time. Eur Radiol (2016) 0.79
Is color-Doppler US a reliable method in the follow-up of transjugular intrahepatic portosystemic shunt (TIPS)? J Ultrasound (2007) 0.78
Carvedilol in the treatment of portal hypertension. Saudi J Gastroenterol (2011) 0.77
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Synergism between hepatocellular injury and shunting in portosystemic encephalopathy (PSE): case report of acute brittle TIPS-induced PSE. Dig Dis Sci (2007) 0.76
Impact of splenic circulation: non-invasive microbubble-based assessment of portal hemodynamics. Eur Radiol (2014) 0.76
Management of cirrhotic ascites. Ther Adv Chronic Dis (2015) 0.75
Quantitative modeling of the physiology of ascites in portal hypertension. BMC Gastroenterol (2012) 0.75
A Case of Isolated Duodenal Varices Secondary to Chronic Pancreatitis with Review of Literature. Gastroenterology Res (2010) 0.75
The modified Sugiura procedure as bridge surgery for liver transplantation: a case report. J Med Case Rep (2015) 0.75
Role of endoscopy in management of gastrointestinal complications of portal hypertension. World J Gastrointest Endosc (2015) 0.75
Passive expansion of sub-maximally dilated transjugular intrahepatic portosystemic shunts and assessment of clinical outcomes. World J Hepatol (2017) 0.75
Percutaneous Portosystemic Shunts: TIPS and Beyond. Semin Intervent Radiol (2014) 0.75
Laparoscopic Splenectomy and Azygoportal Disconnection: a Systematic Review. JSLS (2016) 0.75
A case of successful management with splenectomy of intractable ascites due to congenital dyserythropoietic anemia type II-induced cirrhosis. World J Gastroenterol (2006) 0.75
Clinical events after TIPS: correlation with hemodynamic findings. Gastroenterology (1998) 0.75
Outcomes of TIPS for Treatment of Gastroesophageal Variceal Hemorrhage. Semin Intervent Radiol (2014) 0.75
The Evolution of Transjugular Intrahepatic Portosystemic Shunt: Tips. ISRN Hepatol (2014) 0.75
Transjugular Intrahepatic Portosystemic Shunt Dysfunction: Concordance of Clinical Findings, Doppler Ultrasound Examination, and Shunt Venography. J Clin Imaging Sci (2016) 0.75
Clinically severe portal hypertension: role of multi-detector row CT features in diagnosis. Dig Dis Sci (2014) 0.75
Evaluation of Doppler-ultrasonography in the diagnosis of transjugular intrahepatic portosystemic shunt dysfunction: A prospective study. World J Hepatol (2017) 0.75
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 29.25
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet (2006) 15.32
Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology (2001) 6.88
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med (2001) 6.38
Relation between portal pressure response to pharmacotherapy and risk of recurrent variceal haemorrhage in patients with cirrhosis. Lancet (1995) 6.06
Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N Engl J Med (1999) 5.89
Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology (1999) 5.64
Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med (2000) 5.09
Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology (1988) 4.32
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation (2001) 3.96
Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology (1998) 3.62
Ramipril and the development of diabetes. JAMA (2001) 3.38
Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology (1993) 3.28
The treatment of portal hypertension: a meta-analytic review. Hepatology (1995) 3.11
Compensated cirrhosis: natural history and prognostic factors. Hepatology (1987) 3.01
Hemodynamic events in a prospective randomized trial of propranolol versus placebo in the prevention of a first variceal hemorrhage. Gastroenterology (1990) 2.99
Surgical resection of hepatocellular carcinoma in cirrhotic patients: prognostic value of preoperative portal pressure. Gastroenterology (1996) 2.96
Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet (1989) 2.94
Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol (2001) 2.73
Effects of somatostatin on renal function in cirrhosis. Gastroenterology (1992) 2.68
Angiotensin II induces contraction and proliferation of human hepatic stellate cells. Gastroenterology (2000) 2.57
Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology (1995) 2.47
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation (2001) 2.30
Occult microlithiasis in 'idiopathic' acute pancreatitis: prevention of relapses by cholecystectomy or ursodeoxycholic acid therapy. Gastroenterology (1991) 2.29
Renal impairment after spontaneous bacterial peritonitis in cirrhosis: incidence, clinical course, predictive factors and prognosis. Hepatology (1994) 2.27
Comparison of heparin and steroids in the treatment of moderate and severe ulcerative colitis. Gastroenterology (2000) 2.22
Reduced mRNA abundance of the main enzymes involved in methionine metabolism in human liver cirrhosis and hepatocellular carcinoma. J Hepatol (2000) 2.22
Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis (1999) 2.15
A multicenter, randomized, clinical trial of hormonal therapy in the prevention of rebleeding from gastrointestinal angiodysplasia. Gastroenterology (2001) 2.14
S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol (1999) 2.14
[Diagnosis of renal carcinoma in acquired cystic renal disease. Usefulness of echography in detection during subclinical phase]. Med Clin (Barc) (1991) 2.04
Randomized, comparative study of oral ofloxacin versus intravenous cefotaxime in spontaneous bacterial peritonitis. Gastroenterology (1996) 2.00
Treatment of small hepatocellular carcinoma in cirrhotic patients: a cohort study comparing surgical resection and percutaneous ethanol injection. Hepatology (1993) 1.97
Beta-blockade with propranolol and hepatic artery blood flow in patients with cirrhosis. Hepatology (1989) 1.97
Complications of cirrhosis. I. Portal hypertension. J Hepatol (2000) 1.96
Prognostic significance of hepatic encephalopathy in patients with cirrhosis. J Hepatol (1999) 1.92
Circulating levels of endothelin in cirrhosis. Gastroenterology (1993) 1.91
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J (2004) 1.90
Hepatopulmonary syndrome in candidates for liver transplantation. J Hepatol (2001) 1.89
Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet (1991) 1.88
Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems. Hepatology (1998) 1.87
Comparison of rifampicin with phenobarbitone for treatment of pruritus in biliary cirrhosis. Lancet (1989) 1.86
Histological course of alcoholic hepatitis. Influence of abstinence, sex and extent of hepatic damage. J Hepatol (1986) 1.84
Liver transplantation for small hepatocellular carcinoma: the tumor-node-metastasis classification does not have prognostic power. Hepatology (1998) 1.83
Impaired responsiveness to angiotensin II in experimental cirrhosis: role of nitric oxide. Hepatology (1993) 1.79
Gastric mucosal vascular ectasias causing bleeding in cirrhosis. A distinct entity associated with hypergastrinemia and low serum levels of pepsinogen I. Gastroenterology (1987) 1.77
Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. J Hepatol (1998) 1.76
Prognostic value of arterial pressure, endogenous vasoactive systems, and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology (1988) 1.76
Malignant colorectal obstruction treated by means of self-expanding metallic stents: effectiveness before surgery and in palliation. Radiology (2000) 1.76
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Atrial natriuretic factor in cirrhosis with ascites: plasma levels, cardiac release and splanchnic extraction. Hepatology (1988) 1.74
Hepatocellular carcinoma and cirrhosis. Results of surgical treatment in a European series. Ann Surg (1996) 1.73
Randomized trial comparing albumin, dextran 70, and polygeline in cirrhotic patients with ascites treated by paracentesis. Gastroenterology (1996) 1.68
Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology (1990) 1.67
Nitroglycerin improves the hemodynamic response to vasopressin in portal hypertension. Hepatology (1983) 1.67
Multicenter randomized controlled trial of terlipressin versus sclerotherapy in the treatment of acute variceal bleeding: the TEST study. Hepatology (2000) 1.67
Hemodynamic and humoral changes after liver transplantation in patients with cirrhosis. Hepatology (1993) 1.67
Fulminant hepatic failure. Lancet (1997) 1.66
In vitro and in vivo activation of rat hepatic stellate cells results in de novo expression of L-type voltage-operated calcium channels. Hepatology (2001) 1.66
Prognostic value of early measurements of portal pressure in acute variceal bleeding. Gastroenterology (1999) 1.64
Double-blind randomized controlled trial comparing terlipressin and somatostatin for acute variceal hemorrhage. Variceal Bleeding Study Group. Gastroenterology (1996) 1.64
Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension. Gastroenterology (2001) 1.62
Carvedilol, a new nonselective beta-blocker with intrinsic anti- Alpha1-adrenergic activity, has a greater portal hypotensive effect than propranolol in patients with cirrhosis. Hepatology (1999) 1.62
Tumor necrosis factor and interleukin-6 in spontaneous bacterial peritonitis in cirrhosis: relationship with the development of renal impairment and mortality. Hepatology (1998) 1.60
The lung in patients with cirrhosis. J Hepatol (1990) 1.59
Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis (1976) 1.59
Is hepatitis C virus infection a trigger of porphyria cutanea tarda? Lancet (1993) 1.57
Increased gastric mucosal perfusion in cirrhotic patients with portal hypertensive gastropathy. Gastroenterology (1992) 1.57